Sun Pharma Advanced Research Company Limited (SPARC.BO)
INR 124.6
(-1.27%)
INR 124.6
(-1.27%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.73 Billion INR | -94.88% |
| 2022 | -2.03 Billion INR | -11.37% |
| 2021 | -1.79 Billion INR | -41.86% |
| 2020 | -1.29 Billion INR | 57.47% |
| 2019 | -3 Billion INR | -111.57% |
| 2018 | -1.37 Billion INR | 39.99% |
| 2017 | -1.88 Billion INR | -121.73% |
| 2016 | -1.08 Billion INR | -81.21% |
| 2015 | -599.77 Million INR | -86.55% |
| 2014 | -317.83 Million INR | -182.99% |
| 2013 | 437.72 Million INR | 342.27% |
| 2012 | -148.7 Million INR | 76.68% |
| 2011 | -687.94 Million INR | -1160.26% |
| 2010 | -53.94 Million INR | 70.91% |
| 2009 | -187.69 Million INR | -84.57% |
| 2008 | -101.69 Million INR | -209.99% |
| 2007 | -32.8 Million INR | -88.76% |
| 2006 | -17.34 Million INR | 0.0% |
| 2005 | - INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -933.6 Million INR | 9.94% |
| 2024 Q2 | -1.02 Billion INR | -12.06% |
| 2023 Q4 | -1.05 Billion INR | -9.98% |
| 2023 Q2 | -829.8 Million INR | 9.79% |
| 2023 Q1 | -919.9 Million INR | -16.68% |
| 2023 FY | - INR | -94.88% |
| 2023 Q3 | -962.3 Million INR | -15.97% |
| 2022 FY | - INR | -11.37% |
| 2022 Q1 | -780.2 Million INR | -17.65% |
| 2022 Q2 | -625.4 Million INR | 19.84% |
| 2022 Q3 | -829.8 Million INR | -32.68% |
| 2022 Q4 | -788.38 Million INR | 4.99% |
| 2021 FY | - INR | -41.86% |
| 2021 Q1 | -534.7 Million INR | -6.74% |
| 2021 Q3 | -109.3 Million INR | 77.78% |
| 2021 Q2 | -491.9 Million INR | 8.0% |
| 2021 Q4 | -663.14 Million INR | -506.72% |
| 2020 FY | - INR | 57.47% |
| 2020 Q1 | 614.4 Million INR | 164.51% |
| 2020 Q2 | -795.5 Million INR | -229.48% |
| 2020 Q3 | -613.6 Million INR | 22.87% |
| 2020 Q4 | -500.95 Million INR | 18.36% |
| 2019 FY | - INR | -111.57% |
| 2019 Q1 | -913.5 Million INR | -515.74% |
| 2019 Q4 | -952.38 Million INR | -79.69% |
| 2019 Q3 | -530 Million INR | 12.63% |
| 2019 Q2 | -606.6 Million INR | 33.6% |
| 2018 Q1 | -625.6 Million INR | -40.68% |
| 2018 FY | - INR | 39.99% |
| 2018 Q4 | -148.35 Million INR | 77.89% |
| 2018 Q3 | -671 Million INR | -10550.79% |
| 2018 Q2 | -6.3 Million INR | 98.99% |
| 2017 Q1 | -767.1 Million INR | -157.59% |
| 2017 FY | - INR | -121.73% |
| 2017 Q4 | -444.7 Million INR | 20.63% |
| 2017 Q3 | -560.3 Million INR | 7.34% |
| 2017 Q2 | -604.7 Million INR | 21.17% |
| 2016 Q3 | -639 Million INR | -464.1% |
| 2016 FY | - INR | -81.21% |
| 2016 Q4 | -297.8 Million INR | 53.4% |
| 2016 Q2 | 175.5 Million INR | 153.47% |
| 2016 Q1 | -328.2 Million INR | -419.3% |
| 2015 Q3 | -384.6 Million INR | -145.12% |
| 2015 Q2 | -156.9 Million INR | -7231.82% |
| 2015 Q4 | -63.2 Million INR | 83.57% |
| 2015 FY | - INR | -86.55% |
| 2015 Q1 | 2.2 Million INR | 102.91% |
| 2014 Q4 | -75.72 Million INR | 55.59% |
| 2014 FY | - INR | -182.99% |
| 2014 Q3 | -170.5 Million INR | -2764.06% |
| 2014 Q2 | 6.4 Million INR | 107.92% |
| 2014 Q1 | -80.8 Million INR | -292.96% |
| 2013 Q4 | -20.56 Million INR | -105.49% |
| 2013 FY | - INR | 342.27% |
| 2013 Q2 | -46.8 Million INR | -136.56% |
| 2013 Q1 | 128 Million INR | -72.63% |
| 2013 Q3 | 374.3 Million INR | 899.79% |
| 2012 Q1 | -173.7 Million INR | 16.11% |
| 2012 Q3 | -220 Million INR | 2.4% |
| 2012 Q4 | 467.61 Million INR | 312.55% |
| 2012 FY | - INR | 76.68% |
| 2012 Q2 | -225.4 Million INR | -29.76% |
| 2011 Q3 | -170.4 Million INR | 0.0% |
| 2011 FY | - INR | -1160.26% |
| 2011 Q4 | -207.05 Million INR | -21.51% |
| 2010 FY | - INR | 70.91% |
| 2009 FY | - INR | -84.57% |
| 2008 FY | - INR | -209.99% |
| 2007 FY | - INR | -88.76% |
| 2006 FY | - INR | 0.0% |
| 2005 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bal Pharma Limited | 345.59 Million INR | 1179.674% |
| Achyut Healthcare Limited | 524 Thousand INR | 712174.046% |
| Alkem Laboratories Limited | 24.19 Billion INR | 115.422% |
| Divi's Laboratories Limited | 25.43 Billion INR | 114.673% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 132.893% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 154.369% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | -4410.339% |
| Mankind Pharma Limited | 28.09 Billion INR | 113.281% |
| Medicamen Biotech Limited | 245.66 Million INR | 1618.875% |
| Medico Remedies Limited | 150.37 Million INR | 2581.259% |
| Megasoft Limited | 284.73 Million INR | 1410.454% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 223.781% |
| Piramal Pharma Limited | 13.05 Billion INR | 128.58% |
| Sequent Scientific Limited | 549.8 Million INR | 778.659% |
| Sigachi Industries Limited | 883.39 Million INR | 522.377% |
| Ajanta Pharma Limited | 12.56 Billion INR | 129.695% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 102.697% |
| Brooks Laboratories Limited | 41.72 Million INR | 9041.881% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 195.443% |
| Themis Medicare Limited | 562.6 Million INR | 763.21% |
| Unichem Laboratories Limited | 742.35 Million INR | 602.625% |
| Hester Biosciences Limited | 539.47 Million INR | 791.654% |
| Venus Remedies Limited | 711.8 Million INR | 624.201% |
| Indoco Remedies Limited | 2.64 Billion INR | 240.959% |
| Ind-Swift Limited | 1.06 Billion INR | 450.332% |
| Aarti Drugs Limited | 3.24 Billion INR | 214.857% |
| Alpa Laboratories Limited | 86.12 Million INR | 4432.286% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 258.319% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 104.227% |
| Granules India Limited | 8.6 Billion INR | 143.368% |
| Gufic Biosciences Limited | 1.48 Billion INR | 352.03% |
| Hikal Limited | 2.69 Billion INR | 238.594% |
| RPG Life Sciences Limited | 1.28 Billion INR | 391.164% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 179.776% |
| Windlas Biotech Limited | 781.72 Million INR | 577.315% |
| ZIM Laboratories Limited | 462.09 Million INR | 907.464% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 154.379% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 243.147% |
| Jubilant Pharmova Limited | 8 Billion INR | 146.606% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 106.039% |
| Bajaj HealthCare Limited | 444.51 Million INR | 939.4% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | 28665.825% |
| Ipca Laboratories Limited | 13.29 Billion INR | 128.056% |
| Lasa Supergenerics Limited | -65.08 Million INR | -5633.356% |
| Laurus Labs Limited | 8 Billion INR | 146.606% |
| NATCO Pharma Limited | 18.79 Billion INR | 119.852% |
| Nectar Lifesciences Limited | 1.56 Billion INR | 338.604% |
| Shilpa Medicare Limited | 2.58 Billion INR | 244.177% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | -32.225% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 110.658% |
| Wanbury Limited | 985.49 Million INR | 478.621% |
| Wockhardt Limited | 1.08 Billion INR | 445.488% |
| Strides Pharma Science Limited | 3.76 Billion INR | 199.112% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 352.278% |
| Suven Life Sciences Limited | -992.78 Million INR | -275.84% |
| Amrutanjan Health Care Limited | 682.53 Million INR | 646.675% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 138.8% |
| Eris Lifesciences Limited | 6.98 Billion INR | 153.407% |
| Lupin Limited | 36.96 Billion INR | 110.093% |
| Syncom Formulations (India) Limited | 430.27 Million INR | 967.18% |
| Valiant Laboratories Limited | 12.73 Million INR | 29390.117% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 106.637% |
| FDC Limited | 4.4 Billion INR | 184.769% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 139.972% |
| Novartis India Limited | 1.26 Billion INR | 393.963% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | 1253.549% |
| Neuland Laboratories Limited | 4.74 Billion INR | 178.583% |
| Morepen Laboratories Limited | 1.72 Billion INR | 316.186% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | 1398.171% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | 2232.811% |